Mineralys Therapeutics reports inducement awards under Nasdaq Rule 5635(c)(4)
RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. NASDAQ:MLYS, a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and ot…
Story updates
08:11:27 PM UTC
SquawkNews
RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. NASDAQ:MLYS, a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and ot…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.